E-LIB Suche - Ergebnisse für: Ho, Alan L.

1

A phase 1 study of concurrent cabozantinib and cetuximab in..:

Desilets, Antoine ; Pfister, David G. ; Stein, Sarah...
Oral Oncology. 154 (2024) - p. 106861 , 2024

Link: https://doi.org/10.1016/..

2

Evolutionary dynamics of tipifarnib in HRAS mutated head an..:

Jagadeeshan, Sankar ; Suryamohan, Kushal ; Shin, Nara...
Oral Oncology. 149 (2024) - p. 106688 , 2024

Link: https://doi.org/10.1016/..

3

A Phase II Trial of Rivoceranib, an Oral Vascular Endotheli..:

Hanna, Glenn J. ; Ahn, Myung-Ju ; Muzaffar, Jameel...
Clinical Cancer Research. 29 (2023) 22 - p. 4555-4563 , 2023

Link: https://doi.org/10.1158/..

4

Nivolumab in salivary gland cancers: confronting the challe..:

Desilets, Antoine ; Ho, Alan L
BMJ Oncology. 2 (2023) 1 - p. e000214 , 2023

Link: https://doi.org/10.1136/..

5

Clinical-genomic determinants of immune checkpoint blockade..:

Valero, Cristina ; Golkaram, Mahdi ; Vos, Joris L....
Journal of Clinical Investigation. , 2023

Link: https://doi.org/10.1172/..

6

A phase 2 study of MK‐2206 in patients with incurable adeno..:

Ho, Alan L. ; Foster, Nathan R. ; Deraje Vasudeva, Shyamprasad...
Cancer. 130 (2023) 5 - p. 702-712 , 2023

Link: https://doi.org/10.1002/..

7

Nivolumab plus ipilimumab in advanced salivary gland cancer..:

Vos, Joris L. ; Burman, Bharat ; Jain, Swati...
Nature Medicine. 29 (2023) 12 - p. 3077-3089 , 2023

Link: https://doi.org/10.1038/..

8

Tipifarnib Potentiates the Antitumor Effects of PI3Kα Inhib..:

Smith, Alison E. ; Chan, Stacia ; Wang, Zhiyong...
Cancer Research. 83 (2023) 19 - p. 3252-3263 , 2023

Link: https://doi.org/10.1158/..

9

The use of single-timepoint images to link administered rad..:

Mauguen, Audrey ; Grewal, Ravinder K. ; Augensen, Finn...
European Journal of Nuclear Medicine and Molecular Imaging. 50 (2023) 10 - p. 2971-2983 , 2023

Link: https://doi.org/10.1007/..

10

The evolving landscape of salivary gland tumors:

Steuer, Conor E. ; Hanna, Glenn J. ; Viswanathan, Kartik...
CA: A Cancer Journal for Clinicians. 73 (2023) 6 - p. 597-619 , 2023

Link: https://doi.org/10.3322/..

11

Toward individualized dosimetry for radiopharmaceutical the..:

Bodei, Lisa ; Michael Tuttle, R. ; Grewal, Ravinder K....
European Journal of Nuclear Medicine and Molecular Imaging. 51 (2023) 2 - p. 325-329 , 2023

Link: https://doi.org/10.1007/..

12

Loss of CDKN2A/B is a Molecular Marker of High-grade Histol..:

Dogan, Snjezana ; Xu, Bin ; Rana, Satshil...
Modern Pathology. 36 (2023) 7 - p. 100150 , 2023

Link: https://doi.org/10.1016/..

13

Genomic characterization of metastatic patterns from prospe..:

Nguyen, Bastien ; Fong, Christopher ; Luthra, Anisha...
Cell. 185 (2022) 3 - p. 563-575.e11 , 2022

Link: https://doi.org/10.1016/..

14

Consensuses, controversies, and future directions in treatm..:

Kang, Jung Julie ; Yu, Yao ; Chen, Linda...
CA: A Cancer Journal for Clinicians. 73 (2022) 2 - p. 164-197 , 2022

Link: https://doi.org/10.3322/..

15

Larotrectinib Treatment for Patients With TRK Fusion-Positi..:

Le, Xiuning ; Baik, Christina ; Bauman, Jessica...
The Oncologist. 29 (2022) 6 - p. e779-e788 , 2022

Link: https://doi.org/10.1093/..